Moreover, a case reported that with dasatinib (BMS‐354825) (Src/ABL tyrosine kinase inhibitor) treatment, a chronic myeloid leukemia (CML) patient went into remission after experiencing severe SARS‐CoV‐2 infection and symptoms; this suggests that ABL kinase may play a critical role in viral egress and is a potentially attractive target for coronavirus replication.80 The gene discussed is SRC; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.